Significant Increase in Antitumor Potency of Doxorubicin Hc1 by its Encapsulation in Pegylated Liposomes

References

• Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891–896
   PubMed Web of Science ®Google Scholar
• Cabanes A., Tzemach D., Goren D., Horowitz A.T., Gabizon A. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 1998; 4: 499–505
   PubMed Web of Science ®Google Scholar
• Vaage J., Donovan D., Uster P., Working P. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xeno-grafted human pancreatic carcinoma. Br J Cancer 1997; 75: 482–486
   PubMed Web of Science ®Google Scholar
• Gabizon A., Goren D., Horowitz A.T., Tzemach D., Lossos A., Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: A review of biodis-tribution studies in tumor-bearing animals. Adv Drug Delivery Rev, 24: 337–344
   Google Scholar
• Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol-coated liposomes. Cancer Res 1994; 54: 987–992
   PubMed Web of Science ®Google Scholar
• Vaage J., Uster P., Working P.K. Therapy of human carcinoma xenografts with doxorubicin encapsulated in sterically stabilized liposomes (DOXIL): Efficacy and safety studies in Sterically Stabilized Liposomes: Old Drugs, New Therapeutics, M. Woodle, G. Storm. Academic Press, New York, New York 1997; 61–72, 1997
   Google Scholar
• Sakakibara T., Chen F.A., Kida H., Kunieda K., Cuenca R.E., Martin F.J., Bankert R.B. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 1996; 56: 3743–3746
   PubMed Web of Science ®Google Scholar
• Cay O., Kruskal J.B., Nasser I., Thomas P., Clouse M.E. Liver metastases from colorectal cancer: Drug delivery with liposome-encapsulated doxorubicin. Radiology 1997; 205: 95–101
   PubMed Web of Science ®Google Scholar
• Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.-J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987–993
   PubMed Web of Science ®Google Scholar
• Ranson M.R., Carmichael J., O'Byrne K., Stewart S., Smith D., Howell A. Treatment of Advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185–3191
   PubMed Web of Science ®Google Scholar
• Northfelt D.W., Martin F.J., Working P.K., Volberding P.A., Russell J., Newman M., Amantea M.A., Kaplan L.D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36: 55–63
   PubMed Web of Science ®Google Scholar
• Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F. M., Gabizon A. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777–1785
   PubMed Web of Science ®Google Scholar
• Gabizon A., Peretz T., Sulkes A., Amselem S., Ben-Yosef R., Ben-Baruch N., Catane R., Biran S., Barenholz Y. Systemic administration of doxorubi-cin-containing liposomes in cancer patients: A phase I study. Eur J Cancer Clin Oncol 1989; 25: 1795–1803
   PubMedGoogle Scholar
• Doroshow J.H. Anthracyclines and Anthracenediones in Cancer Chemotherapy and Biotherapy: Principles and Practice, B.A. Chabner, D.L. Longo. Lippincott - Raven, PhiladelphiaPennsylvania 1996; 409–434
   Google Scholar
• Berry G., Billingham M., Alderman E., Richardson P., Torti F., Lum B., Patek A., Martin F.J. The use of a cardiac biopsy to demonstrate reduced cardio-toxicity in AIDS Kaposi's Sarcoma patients treated with pegylated liposomal doxorubicin. Annals Oncology 1998; 9: 711–716
   PubMed Web of Science ®Google Scholar
• Working P.K., Newman M.S., Sullivan T., Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long circulating pegylated (STEALTH*) liposomes. J Pharmacol Exp Therap 1998; 289: 1128–1133
   Google Scholar
• Working P.K., Newman M.S., Carter J.L., Kerl R.E., Kiorpes A.L. Comparative target organ toxicity of free and liposome-encapsulated doxorubicin in rats. The Toxicologist 1994; 14: 217
   Google Scholar
• Working P.K., Dayan A.D. Pharmacological-toxicological expert report. CAELYX® (Stealth5 liposomal doxorubicin HC1). Human Exp Toxicol 1996; 15: 752–785
   Web of Science ®Google Scholar
• Vaage J., Barbera-Guillem E., Abra R.A., Huang A., Working P.K. Tissue distributions and therapeutic effects of intravenous free or encapsulated liposomal doxorubicin on human prostatic carcinoma xenografts. Cancer 1994; 73: 1478–1484
   PubMed Web of Science ®Google Scholar
• Davis I.D. A method for minimizing the effects of biologic diversity on the measurement of tumor growth rates. Contemporary Topics 1997; 36: 80–85
   Google Scholar